Skip to main content
SpringerLink
Log in

DuoResp Spiromax forecast to save asthma costs in Spain

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Darba J, et al. A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions. ClinicoEconomics and Outcomes Research 2016: 435-444, No. 8, 6 Sep 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S111453

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DuoResp Spiromax forecast to save asthma costs in Spain. PharmacoEcon Outcomes News 762, 17 (2016). https://doi.org/10.1007/s40274-016-3393-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3393-6

Search

Navigation